DDInter1256 DDInter899
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nafcillin {u} (Compound) resembles {v} (Compound) Flucloxacillin
Nafcillin {u} (Compound) resembles {v} (Compound) Mezlocillin
Nafcillin {u} (Compound) binds {v} (Gene) SLC22A6
Nafcillin {u} (Compound) upregulates {v} (Gene) SATB1
Nafcillin {u} (Compound) is included by {v} (Pharmacologic Class) Penicillins
Nafcillin {u} (Compound) downregulates {v} (Gene) COPS7A
Nafcillin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Nafcillin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Nafcillin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Nafcillin (Compound) resembles Flucloxacillin (Compound)
Nafcillin (Compound) resembles Mezlocillin (Compound)
Nafcillin (Compound) binds SLC22A6 (Gene)
Nafcillin (Compound) upregulates SATB1 (Gene)
Nafcillin (Compound) is included by Penicillins (Pharmacologic Class)
Nafcillin (Compound) downregulates COPS7A (Gene)
Nafcillin (Compound) causes Gastrointestinal disorder (Side Effect)
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone